AR064263A1 - Composiciones farmaceuticas que comprenden un compuesto bisfosfato - Google Patents

Composiciones farmaceuticas que comprenden un compuesto bisfosfato

Info

Publication number
AR064263A1
AR064263A1 ARP070105121A ARP070105121A AR064263A1 AR 064263 A1 AR064263 A1 AR 064263A1 AR P070105121 A ARP070105121 A AR P070105121A AR P070105121 A ARP070105121 A AR P070105121A AR 064263 A1 AR064263 A1 AR 064263A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
bisfosfato
composite
butanol
topical administration
Prior art date
Application number
ARP070105121A
Other languages
English (en)
Spanish (es)
Original Assignee
Besins Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06291786A external-priority patent/EP1923050A1/en
Priority claimed from EP06291785A external-priority patent/EP1923049A1/en
Application filed by Besins Healthcare filed Critical Besins Healthcare
Publication of AR064263A1 publication Critical patent/AR064263A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP070105121A 2006-11-17 2007-11-16 Composiciones farmaceuticas que comprenden un compuesto bisfosfato AR064263A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86629406P 2006-11-17 2006-11-17
US86630606P 2006-11-17 2006-11-17
EP06291786A EP1923050A1 (en) 2006-11-17 2006-11-17 Liquid pharmaceutical compositions comprising a bisphosphonate compound
EP06291785A EP1923049A1 (en) 2006-11-17 2006-11-17 Pharmaceutical compositions comprising a bisphosphonate compound

Publications (1)

Publication Number Publication Date
AR064263A1 true AR064263A1 (es) 2009-03-25

Family

ID=38895592

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070105121A AR064263A1 (es) 2006-11-17 2007-11-16 Composiciones farmaceuticas que comprenden un compuesto bisfosfato
ARP070105120A AR064262A1 (es) 2006-11-17 2007-11-16 Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP070105120A AR064262A1 (es) 2006-11-17 2007-11-16 Composiciones farmaceuticas liquidas que comprenden un compuesto bisfosfonato

Country Status (9)

Country Link
US (2) US20080182822A1 (enExample)
EP (2) EP2114368A1 (enExample)
JP (2) JP2010510195A (enExample)
AR (2) AR064263A1 (enExample)
AU (2) AU2007321108A1 (enExample)
CA (2) CA2669488A1 (enExample)
IL (2) IL198678A0 (enExample)
TW (2) TW200829282A (enExample)
WO (2) WO2008059059A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008059059A1 (en) * 2006-11-17 2008-05-22 Besins Healthcare Pharmaceutical compositions comprising a bisphosphonate compound
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
KR101813728B1 (ko) 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
WO2019232114A1 (en) * 2018-06-01 2019-12-05 The University Of North Carolina At Chapel Hill Injectable thermoresponsive hydrogels as a combinatory modality for controlled drug delivery, biomaterial implant and 3d printing bioink

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX21453A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
JP3411690B2 (ja) * 1994-09-21 2003-06-03 帝人株式会社 局所投与用アレンドロン酸ナトリウム製剤
US6905701B2 (en) * 1997-06-11 2005-06-14 Umd, Inc. Formulations for transmucosal vaginal delivery of bisphosphonates
US6416737B1 (en) * 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
US20050074487A1 (en) * 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
JP2001253827A (ja) * 2000-02-15 2001-09-18 Pfizer Prod Inc 骨粗鬆症を治療するための組成物および方法
KR100492110B1 (ko) * 2000-05-05 2005-06-02 에프. 호프만-라 로슈 아게 비스포스폰산 또는 그의 염을 포함하는 피하 투여용겔-유사 약학 조성물
JP4394888B2 (ja) * 2002-02-14 2010-01-06 救急薬品工業株式会社 経皮投与製剤
US7820197B2 (en) * 2002-02-14 2010-10-26 Astellas Pharma Inc. Percutaneous preparations
CA2532212A1 (en) * 2003-07-11 2005-01-27 Macrochem Corporation Pharmaceutical compositions for topical application
MY141763A (en) * 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
US20050119230A1 (en) * 2003-09-18 2005-06-02 Alexandra Glausch Pharmaceutical products comprising bisphosphonated
WO2005037157A1 (en) * 2003-10-14 2005-04-28 Dermatrends, Inc. Enhancing transdermal administration of hydrophilic drugs
WO2008059059A1 (en) * 2006-11-17 2008-05-22 Besins Healthcare Pharmaceutical compositions comprising a bisphosphonate compound

Also Published As

Publication number Publication date
TW200831130A (en) 2008-08-01
JP2010510194A (ja) 2010-04-02
CA2669488A1 (en) 2008-05-22
IL198698A0 (en) 2010-02-17
AU2007321109A2 (en) 2009-06-11
US20080167271A1 (en) 2008-07-10
CA2669489A1 (en) 2008-05-22
WO2008059060A1 (en) 2008-05-22
AU2007321108A1 (en) 2008-05-22
JP2010510195A (ja) 2010-04-02
IL198678A0 (en) 2010-02-17
TW200829282A (en) 2008-07-16
AU2007321109A1 (en) 2008-05-22
WO2008059059A1 (en) 2008-05-22
AR064262A1 (es) 2009-03-25
US20080182822A1 (en) 2008-07-31
EP2114368A1 (en) 2009-11-11
EP2088996A1 (en) 2009-08-19

Similar Documents

Publication Publication Date Title
AR064263A1 (es) Composiciones farmaceuticas que comprenden un compuesto bisfosfato
ES2478264T3 (es) Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica
PE20080374A1 (es) Composiciones farmaceuticas de ropinirol
AR065039A1 (es) Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso
HRP20191806T1 (hr) Transdermalni pripravci ibuprofena i postupci za njihovu uporabu
CO6321221A2 (es) Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
DE69901951D1 (de) Verwendung gelierbarer pharmazeutischer zusammensetzungen in der parodontologie
BRPI0509708A (pt) composição de espuma de pimecrolimus contendo glicol de hexileno, opcionalmente álcool de oleil, dimetilisosorbìdeo e/ou triglicerìdeos de cadeia média
HRP20040323C1 (hr) Oralni oblici davanja propiverina ili njegovih farmaceutski prihvatljivih soli s produljenim oslobađanjem djelotvone supstance
PE20120476A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
ATE526956T1 (de) Viruzide zusammensetzungen
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
AR063109A1 (es) Terapias topicas para la mucositis oral y otras afecciones
JP5739542B2 (ja) オーラルケア組成物
PE20200698A1 (es) Gel que comprende clorhexidina
BRPI0508933A (pt) composições para entrega tópica
CY1108548T1 (el) Βιοπροσκολλητικη γελη βασισμενη σε υδροξυαιθυλοκυτταρινη
ES2720954T3 (es) Formulaciones estabilizadas de estatina
AR050463A1 (es) Analagos de lonidamina y su uso en anticoncepcion masculina y en el tratamiento contra el cancer.
ES2637891T3 (es) Composiciones de complementos dietéticos antioxidantes y métodos para conservar una piel sana
UY38055A (es) Composiciones oftálmicas de compuestos de bencimidazol para uso unico diario
JP2010510194A5 (enExample)
BRPI0517413A (pt) composições farmacêuticas com gosto mascarado
BR0215303A (pt) Formulações farmacêuticas de base aquosa de pró-drogas solúveis em água de propofol
BRPI0411702B8 (pt) uso de ácido hialurônico para preparar composições para o tratamento de aftas da cavidade oral

Legal Events

Date Code Title Description
FB Suspension of granting procedure